Pierre Morel
Tokyo Medical University
2 papers in the Anchorcite directory, published between 1997 and 2002, cited 10,072 times in total.
ORCID profileResearch topics
- Lymphoma Diagnosis and Treatment · 1 paper
- Viral-associated cancers and disorders · 1 paper
- CNS Lymphoma Diagnosis and Treatment · 1 paper
- Hematopoietic Stem Cell Transplantation · 1 paper
- Acute Myeloid Leukemia Research · 1 paper
- Retinoids in leukemia and cellular processes · 1 paper
Frequent co-authors
- Bertrand Coiffier · 1 paper
- Éric Lepage · 1 paper
- Josette Brière · 1 paper
- Raoul Herbrecht · 1 paper
- Hervé Tilly · 1 paper
- Réda Bouabdallah · 1 paper
- Éric Van Den Neste · 1 paper
- Gilles Andre Salles · 1 paper
Papers
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine · 2002 · 5,644 citations
BACKGROUND: The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in diffuse large-B-cell lymphoma. We conducted a randomized trial to…
- International Scoring System for Evaluating Prognosis in Myelodysplastic SyndromesBlood · 1997 · 4,428 citations
Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to improve on these systems, an International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical…
Metadata from OpenAlex (CC0).